New Hemophilia Data Lead FDA to Delay Decision for BioMarin Gene Therapy
BioMarin Pharmaceutical's submission of additional data for patients treated with its hemophilia A gene therapy, Roctavian, mean that the FDA will push out a regulatory decision to early summer. But it could be worth the wait as analysts anticipate FDA approval and project Roctavian becoming one of BioMarin’s biggest products.